歐洲生物緩衝液市場規模、份額和趨勢分析報告—產業概況和2035年預測

Customize Your Report Customize Your Report 立即购买 立即购买 免费样本报告 免费样本报告
Home Healthcare Europe Biological Buffers Market
请求目录 请求目录 与分析师交谈 与分析师交谈 免费样本报告 免费样本报告 购买前请咨询 提前咨询 立即购买 立即购买

歐洲生物緩衝液市場規模、份額和趨勢分析報告—產業概況和2035年預測

  • Healthcare
  • Published Report
  • Apr 2025
  • Europe
  • 350 页面
  • 桌子數： 302
  • 图号： 33
  • Author : Sachin Pawar
立即购买 立即购买 索取樣品 索取樣品
Nucleus Nucleus

通过敏捷供应链咨询解决关税挑战

供应链生态系统分析现已成为 DBMR 报告的一部分

Europe Biological Buffers Market

市场规模（十亿美元）

CAGR :  % Diagram

Chart Image USD 246.70 Million USD 510.55 Million 2024 2035
Diagram Forecast Period
 2025 –2035
Diagram Market Size (Base Year)
 USD 246.70 Million
Diagram Market Size (Forecast Year)
 USD 510.55 Million
Diagram CAGR
 %
Diagram Major Markets Players
  • F. Hoffmann-La Roche Ltd
  • Bio-Rad Laboratories Inc.
  • Thermo Fisher Scientific Inc.
  • Takara Bio Inc.
  • Merck KGaA

歐洲生物緩衝液市場細分，按緩衝液類型（商品緩衝液和其他鹽基緩衝液）、配方（粉末和液體）、應用（製藥和生物製藥、細胞培養和分子生物學、臨床和診斷應用、化學和工業應用等）、最終用戶（製藥和生物製藥公司、生物技術公司、研究和學術機構、診斷實驗室、合約研究組織 (CRO）

歐洲生物緩衝劑市場

生物緩衝液市場分析與規模

歐洲生物緩衝液市場是指專注於生物緩衝液的生產、分銷和銷售的市場，生物緩衝液是含有弱酸及其共軛鹼（或弱鹼及其共軛酸）的溶液，用於在實驗室和生物醫學環境中維持穩定的 pH 環境。市場涵蓋各種生物緩衝液，包括磷酸鹽緩衝液、Tris緩衝液、HEPES緩衝液等，可滿足生命科學研究、生物技術、製藥和診斷等領域的各種應用。

生物緩衝液市場規模

Data Bridge Market Research 分析，歐洲生物緩衝液市場預計將從 2024 年的 2.467 億美元增至 2035 年的 5.1055 億美元，在 2025 年至 2035 年的預測期內以 6.9% 的複合年增長率大幅增長。除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察外，Data Bridge Market Research 策劃的市場報告還包括深入的專家分析、進出口分析、定價分析、生產消費分析和 PESTLE 分析。

生物緩衝劑市場趨勢

“人工智慧驅動技術的採用日益普及”

生物緩衝市場正在經歷向人工智慧驅動解決方案的重大轉變。隨著實驗室和生物製藥公司優先考慮精確度、效率和法規遵循性，人工智慧和機器學習正在整合到緩衝液配製和品質控制流程中。這些技術有助於優化 pH 穩定性、增強緩衝液性能預測並簡化生產工作流程。此外，藥物開發、臨床研究和生物加工等領域對即時監控和自動調整的需求日益增長，也推動了需求的成長。隨著監管標準的收緊和數位轉型的加速，人工智慧驅動的生物緩衝解決方案有望成為行業標準

報告範圍和生物緩衝液市場細分

屬性

生物緩衝液關鍵市場洞察

涵蓋的領域
  • 緩衝液類型：商品緩衝液和其他鹽基緩衝液
  • 劑型：粉末和液體
  • 應用：製藥和生物製藥、細胞培養和分子生物學、臨床和診斷應用、化學和工業應用等
  • 最終用戶：製藥和生物製藥公司、生物技術公司、研究和學術機構、診斷實驗室、合約研究組織 (CRO) 和 CMO

覆蓋國家

德國、英國、法國、義大利、西班牙、俄羅斯、荷蘭、瑞士、土耳其、奧地利、波蘭、愛爾蘭、挪威、歐洲其他地區

主要市場參與者

F. Hoffmann-La Roche Ltd（瑞士）、Bio-Rad Laboratories, Inc.（美國）、Thermo Fisher Scientific Inc.（美國）、Takara Bio Inc.（日本）和 Merck KGaA（德國）等

市場機會
  • 生物醫學研究公私合作經費增加
  • 食品安全與環境檢測分析方法

加值資料資訊集

除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括深入的專家分析、進出口分析、定價分析、生產消費分析和 PESTLE 分析。

生物緩衝液市場定義

生物緩衝液是含有弱酸及其共軛鹼（或弱鹼及其共軛酸）的溶液，其在添加酸或鹼時可抵抗 pH 值的變化。它們在生物系統和實驗室環境中對於維持穩定的 pH 環境至關重要，因為酵素和其他生物分子對 pH 波動高度敏感。常見的生物緩衝液包括磷酸鹽、Tris 和 HEPES，每種緩衝液都有適合不同應用的特定緩衝範圍。

歐洲生物緩衝液市場動態

本節涉及了解市場驅動因素、優勢、機會、限制和挑戰。所有這些都將在下面詳細討論：

驅動程式

  • 慢性病盛行率不斷上升

糖尿病、癌症和心血管疾病等慢性疾病的盛行率不斷上升，是歐洲生物緩衝劑市場的重要驅動力。這種增長需要加強研究和開發力度，以了解疾病機制、開發診斷工具和製定有效的治療方法。生物緩衝液在這些努力中發揮著至關重要的作用，因為它們提供了在細胞培養、藥物發現和蛋白質分析等各個領域進行準確實驗和分析所必需的穩定 pH 環境。

例如，

  • 2024年1月，根據NCBI發表的文章，糖尿病、心臟病、中風和癌症等慢性疾病長期以來一直是全球發病率和死亡率的重要因素。這些疾病不僅影響數百萬人的生命，也給全球醫療保健系統帶來巨大壓力。慢性病管理的財務影響預計將大幅上升，預計到 2030 年全球成本將達到 47 兆美元。這驚人的數字凸顯了慢性病日益加重的負擔，需要持續的醫療保健、先進的治療和廣泛的醫療資源
  • 2024 年 7 月，根據世界衛生組織發表的數據，估計到 2023 年底，全球愛滋病毒感染者人數為 3,990 萬 [3,610 萬-4,460 萬]，其中兒童（0-14 歲）140 萬 [1,10 萬-170 萬]，成人（1.5 歲以上） 2023 年，有 130 萬 [100-170 萬] 人感染愛滋病毒。 2023 年，有 12 萬 [8.3-17 萬] 名兒童感染愛滋病毒。 2023 年，有 120 萬 [950-150 萬] 名成年人感染愛滋病毒

這些疾病的盛行率因地區而異，農村地區約有 17% 的老年人患有慢性病，城市地區約有 29% 的老年人患有慢性病。其中，高血壓和糖尿病特別常見，合計約佔老年人口所有慢性病的68%。這凸顯了印度迫切需要有針對性的醫療幹預和管理策略來應對老齡化人口日益加重的慢性病負擔。

Western BLOT 和 Elisa 技術的應用日益廣泛

Western Blot 和 Elisa 技術是生命科學研究和診斷的基礎，可以檢測和量化蛋白質和其他生物分子。隨著研究工作的擴大，特別是在藥物發現、疾病診斷和生物標記識別等領域，對這些技術的需求不斷增長，從而推動了對最佳檢測性能至關重要的高品質、可靠緩衝液的需求。

例如，

  • 2023年4月，根據美國國家醫學圖書館發表的文章，該文強調了ELISA（酶聯免疫吸附試驗）因其在檢測和量化生物物質方面的多功能性、靈敏度和特異性而日益廣泛的應用。採用率的上升是由於其在醫療診斷、食品安全和研究領域的適用性。 ELISA 能夠檢測多種抗原和抗體，再加上自動化和多重使用方面的進步，使其成為臨床和實驗室環境中的首選方法。此檢測方法的簡單性、可重複性和成本效益進一步促進了其使用範圍的擴大
  • 2021年4月，根據IUBMB期刊發表的文章，Western Blot（WB），又稱免疫印跡，是生物學家常用來研究蛋白質生物分子各方面的基本方法。除了研究之外，它還由於能夠直接檢測蛋白質而被廣泛應用於疾病診斷，使其成為臨床環境中常用的高效診斷工具。它的多功能性和可靠性使其在生物實驗室中廣泛採用，並使其成為研究和臨床應用最重要的技術之一

機會

  • 生物醫學研究公私合作經費增加

隨著越來越多的財政資源被分配到科研開發領域，企業有潛力投資於增強阻斷緩衝液性能的創新配方和技術。這筆資金用於支持創建針對特定應用的客製化解決方案，提高特異性並減少檢測中的背景噪音。此外，它還促進了與研究機構的合作，從而帶來了緩衝技術的突破。增加投資有利於環保和永續產品的開發，滿足消費者對環保解決方案日益增長的需求。總體而言，利用這一融資趨勢可以推動阻斷緩衝液市場的進步，並在快速發展的市場環境中增強競爭優勢。

例如，

  • 2021年5月，根據NCBI發表的文章，生物醫學研究的公私資助激增，加上蛋白質印跡技術的應用日益增多和產品創新不斷增加，為成長創造了有利的環境。這一趨勢為阻斷緩衝器市場擴張和發展提供了重要機會
  •  2023年3月，根據NCBI發表的文章，國際生物醫學科學家聯合會Target 2035正在利用開放原則為每種人類蛋白質創造藥理學工具，這對於研究健康和疾病至關重要。由於製藥公司貢獻知識和試劑，這項措施為封閉緩衝液市場的成長和創新提供了寶貴的機會

近期公私融資的激增為阻斷緩衝器市場提供了巨大的機會。增加對科學研究的資金支持使公司能夠投資於改善緩衝性能的創新配方。這筆資金鼓勵開發客製化解決方案，提高特異性，並促進與研究機構的合作，最終推動環保產品的發展。這一趨勢將使阻斷緩衝器市場實現顯著成長。

  • 食品安全與環境檢測分析方法

食品安全和環境檢測等行業越來越依賴精確的分析方法，其中高品質的封閉緩衝液在最大限度地減少背景噪音和提高檢測靈敏度方面發揮關鍵作用。隨著監管標準變得越來越嚴格，這些領域對有效阻斷解決方案的需求將會上升。透過開發專門針對食品安全檢測（如過敏原檢測和病原體識別）和環境監測（如污染物分析）的獨特要求的專用緩衝液，製造商可以進入不斷增長的市場。這種有針對性的方法不僅滿足了特定的行業需求，而且有助於建立競爭優勢。為這些利基應用進行創新並提供可客製化解決方案的公司可能會在更廣泛的阻斷緩衝液市場中實現顯著成長。

例如，

  • 2021年9月，根據Springer Nature發表的文章，酵素連結免疫吸附試驗（ELISA）技術在食品分析中的應用為阻斷緩衝液市場帶來了重大機會。它們的敏感性和特異性可用於檢測各種成分，包括殺蟲劑和毒素。這種多功能性為專門針對食品安全應用的封閉緩衝液創造了寶貴的機會
  • 2020年5月，根據Science Direct發表的文章稱，食品中化學污染的普遍存在為阻斷緩衝液市場帶來了重大機會。競爭性酵素連結免疫吸附試驗 (Cp-ELISA) 因其高通量和低成本而被廣泛用於檢測這些污染物，這凸顯了對有效封閉緩衝液的需求，以提高檢測性能
  • 2020年2月，根據Springer Nature發表的文章，利用酵素連結免疫吸附試驗（ELISA）技術監測水環境中的藥物為阻斷緩衝液市場創造了寶貴的機會。隨著對污染物精確檢測的需求不斷增長，有效的封閉緩衝液對於提高環境檢測的靈敏度和可靠性至關重要

老年人口的成長是歐洲生物緩衝劑市場的主要驅動力，因為老年人更容易患上各種眼部疾病，導致角膜損傷和需要移植。與年齡相關的眼部疾病，例如福克斯內皮營養不良症、大泡性角膜病變和其他退化性角膜疾病，隨著年齡的增長而變得更加普遍，大大增加了對生物緩衝液的需求。此外，老年人更容易出現白內障手術併發症或患有糖尿病等慢性疾病，這會進一步導致角膜惡化。隨著歐洲人口老化，需要生物緩衝的人數預計會增加，特別是在人口老化迅速的地區。人們對生物緩衝液的可用性和成功率的認識不斷提高，以及手術技術的進步為老年患者提供了更好的治療結果和更快的康復時間，進一步推動了這一趨勢。因此，老年人口的增長是推動歐洲生物緩衝劑市場擴張的主要因素，凸顯了對與年齡相關的角膜疾病的可獲得且有效的治療方案的需求。

克制/挑戰

  • 抑制生物緩衝液的替代技術和方法

由於替代方法和先進技術（如無標記檢測和微流體）的興起，生物緩衝液市場面臨著巨大的挑戰，這些技術無需傳統的阻斷緩衝液即可實現精確的相互作用，從而降低了背景噪音。免疫測定方面的創新，包括多路復用，提高了特異性並進一步減少了對傳統阻斷策略的依賴。此外，奈米技術在標靶結合中的應用使生物緩衝液的傳統作用變得複雜。隨著這些替代方案獲得關注，提供具有成本效益的解決方案，它們可能會在敏感的分析中引入背景噪音，從而帶來雙重挑戰。隨著這些方法在研究和臨床應用中越來越廣泛的接受，市場面臨創新和適應的壓力，這可能會改變需求並改變競爭格局。

例如，

  • 2021年7月，根據Springer Nature Limited發表的文章，無細胞基因表現（CFE）為結構生物學和蛋白質體學中基於細胞的傳統蛋白質合成和標記方法提供了一種替代方案。這種創新方法提高了特異性並減少了非特異性相互作用，隨著需求轉向更有效率的方法，對阻斷緩衝液市場提出了挑戰
  • 2024年3月，根據發表在MDPI上的文章，基於pHPMA或聚（2-噁唑啉）的全合成共聚物的合成，旨在抑制非特異性相互作用。這些共聚物可以作為診斷分析中 BSA 或其他蛋白質的潛在替代品，對封閉緩衝液市場構成重大挑戰
  • 2023年8月，根據發表在MDPI上的文章，透過簡化凝膠製備、優化電泳緩衝液、以乙醇取代甲醇等方式增強免疫印跡工藝，提高安全性。這些修改將效率提高了近四倍，甚至可以有效地可視化低品質的抗體。這項創新對阻斷緩衝液市場提出了挑戰。

生物緩衝劑市場範圍

根據緩衝液類型、配方、應用和最終用戶，歐洲生物緩衝液市場分為四個顯著的部分。這些細分市場之間的成長將幫助您分析行業中成長微弱的細分市場，並為用戶提供有價值的市場概覽和市場洞察，幫助他們做出策略決策，確定核心市場應用。

緩衝器類型

  • 貨物緩衝器
    • Tris緩衝液
      • Tris（三（羥甲基）氨基甲烷）
      • 三羥甲基氨基甲烷
      • Tris-鹽酸
    • Hepes緩衝液
      • 赫佩斯
      • B型肝炎病毒
    • 拖把緩衝器
      • 拖把
      • 北美拖把
    • Mes 緩衝器
      • 製造執行系統
      • 梅斯納
    • Bis-Tris緩衝液
      • 比斯-三
      • 雙-三羥甲基氨基甲烷鹽酸鹽
    • 其他的
  • 其他鹽基緩衝液
    • 磷酸鹽緩衝液
      • 磷酸鹽緩衝液（PBS）
      • 磷酸鈉
      • 磷酸鉀
    • 醋酸鹽緩衝液
      • 醋酸鈉
      • 醋酸鉀
    • 檸檬酸鹽緩衝液
      • 檸檬酸鈉
      • 檸檬酸
    • 胺基酸緩衝液
      • 甘氨酸緩衝液
      • 組胺酸緩衝液

配方

  • 粉末
  • 液體

應用

  • 製藥和生物製藥
    • 藥物開發
    • 疫苗配方
    • 生物製劑製造
  • 細胞培養與分子生物學
    • PCR和電泳
    • 細胞培養基製備
    • DNA和RNA分離
    • 蛋白質純化
  • 臨床和診斷應用
    • 體外診斷（IVD）
    • 臨床檢測試劑盒
  • 化學和工業應用
    • 生物技術研究
    • 食品和飲料加工
  • 其他的

最終用戶

  • 製藥和生物製藥公司
  • 生技公司
  • 研究與學術機構
  • 診斷實驗室
  • 合約研究組織 (CROS) 和 CMOS

生物緩衝液市場區域分析

對生物緩衝液市場進行了分析，並根據緩衝液類型、配方、應用和最終用戶提供了市場規模洞察和趨勢。

本市場報告涵蓋的國家包括德國、英國、法國、義大利、西班牙、俄羅斯、荷蘭、瑞士、土耳其、奧地利、波蘭、愛爾蘭、挪威、歐洲其他國家。

由於研發支出高、主要市場參與者的存在、先進的基礎設施、強大的醫療保健系統和嚴格的法規，德國預計將在市場中佔據主導地位。

由於英國醫療保健支出不斷增加、製藥業不斷擴張、醫療保健基礎設施不斷發展以及患病率不斷上升，英國有望成為市場上成長最快的國家。

報告的國家部分還提供了影響市場當前和未來趨勢的個別市場影響因素和市場監管變化。下游和上游價值鏈分析、技術趨勢和波特五力分析、案例研究等數據點是用於預測各國市場情景的一些指標。此外，在對國家數據進行預測分析時，還考慮了區域品牌的存在和可用性及其因來自本地和國內品牌的大量或稀缺的競爭而面臨的挑戰、國內關稅和貿易路線的影響。

歐洲生物緩衝液市場佔有率

市場競爭格局提供了競爭對手的詳細資訊。詳細資訊包括公司概況、公司財務狀況、收入、市場潛力、研發投資、新市場計劃、區域影響力、生產基地和設施、生產能力、公司優勢和劣勢、產品發布、產品寬度和廣度、應用優勢。以上提供的數據點僅與公司對市場的關注有關。

生物緩衝液市場領導者有：

  • F. Hoffmann-La Roche Ltd（瑞士）
  • Bio-Rad Laboratories, Inc.（美國）
  • 賽默飛世爾科技公司（美國）
  • Takara Bio Inc.（日本）、默克集團（德國）、
  • Avantor, Inc.（美國）
  • Advancion公司（美國）
  • 聖克魯斯生物技術公司（美國）
  • MP Biomedicals（美國）
  • Promega公司（美國）
  • 貝克曼庫爾特公司（美國）
  • QIAGEN（德國）
  • HiMedia Laboratories（印度）
  • 開曼化學公司（美國）
  • Biosynth（瑞士）
  • SERVA Electrophoresis GmbH（德）
  • 富士軟片與光純藥株式會社（日本）
  • Reagecon Diagnostics Ltd（愛爾蘭）
  • GoldBio（美國）
  • nacalai.com（日本）
  • 好派克斯（台灣）

生物緩衝液市場的最新發展

  • 2024 年 2 月，羅氏與 PathAI 達成合作協議，以擴展伴隨診斷的數位病理學能力。此次合作為羅氏提供了 PathAI 的先進人工智慧技術，以改善伴隨診斷。它確保獨家、量身定制的解決方案並加速演算法開發，同時讓羅氏繼續開發自己的診斷方法
  • 2024 年 7 月，羅氏在獲得必要的反壟斷和監管批准後宣布成功收購 LumiraDx 的 Point of Care 技術。此次整合增強了羅氏的診斷產品組合，提供了一個用戶友好的平台，整合了各種免疫測定和臨床化學測試。此次收購旨在改善診斷檢測的可近性，特別是在初級保健和服務欠缺地區，這與羅氏對分散式醫療解決方案的承諾一致
  • 2023 年 7 月，Bio-Rad 和 QIAGEN 宣布達成專利和解及交叉授權協議，以解決有關特定技術的持續糾紛。此次合作使兩家公司能夠增強其產品組合，加速生命科學領域的創新，最終透過提供更廣泛的先進技術和改進的研究和診斷解決方案，使客戶受益。
  • 2023 年 5 月，賽默飛世爾科技與 BRIN 合作，提升印尼的研究能力，重點推動當地研究人員在生命科學、生物技術和環境研究領域的科學創新與合作

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

Sample Image Click on image to enlarge
  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE EUROPE BIOLOGICAL BUFFERS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 EUROPE BIOLOGICAL BUFFER MARKET: REGULATIONS

5.1 REGULATORY AUTHORITIES IN THE U.S.

5.2 REGULATORY SUBMISSIONS

5.3 INTERNATIONAL HARMONIZATION

5.4 EUROPE REGULATORY SCENARIO

5.5 REGULATORY SUBMISSIONS

5.6 INTERNATIONAL HARMONIZATION

5.7 JAPAN REGULATORY SCENARIO

5.8 REGULATORY SUBMISSIONS

5.9 INTERNATIONAL HARMONIZATION

5.1 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF CHRONIC DISEASES

6.1.2 INCREASED ADOPTION OF WESTERN BLOT AND ELISA TECHNIQUES

6.1.3 TECHNOLOGICAL ADVANCEMENTS IN ASSAY DEVELOPMENT

6.1.4 ADVANCEMENTS IN PROTEOMICS AND GENOMICS

6.2 RESTRAINTS

6.2.1 LIMITED SHELF LIFE OF BLOCKING BUFFERS

6.2.2 POTENTIAL OF CONTAMINATION OR BATCH INCONSISTENCIES FOR BIOLOGICAL BUFFERS

6.3 OPPORTUNITY

6.3.1 INCREASE IN PUBLIC-PRIVATE FUNDING IN BIOMEDICAL RESEARCH

6.3.2 ANALYTICAL METHODS FOR FOOD SAFETY AND ENVIRONMENTAL TESTING.

6.3.3 DIAGNOSTIC AND CLINICAL APPLICATIONS USE BLOCKING BUFFERS.

6.4 CHALLENGES

6.4.1 ALTERNATIVE TECHNOLOGIES AND APPROACHES FOR INHIBITING BIOLOGICAL BUFFERS.

6.4.2 DISRUPTIONS IN THE SUPPLY CHAIN OF BIOLOGICAL BUFFERS.

7 EUROPE BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE

7.1 OVERVIEW

7.2 GOODS BUFFERS

7.2.1 TRIS BUFFERS

7.2.2 HEPES BUFFERS

7.2.3 MOPS BUFFERS

7.2.4 MES BUFFERS

7.2.5 BIS-TRIS BUFFERS

7.3 OTHER SALT-BASED BUFFERS

7.3.1 PHOSPHATE BUFFERS

7.3.2 ACETATE BUFFERS

7.3.3 CITRATE BUFFERS

7.3.4 AMINO ACID BUFFERS

8 EUROPE BIOLOGICAL BUFFERS MARKET, BY FORMULATION

8.1 OVERVIEW

8.2 POWDER

8.3 LIQUID

9 EUROPE BIOLOGICAL BUFFERS MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 PHARMACEUTICAL & BIOPHARMACEUTICALS

9.3 CELL CULTURE & MOLECULAR BIOLOGY

9.4 CLINICAL & DIAGNOSTIC APPLICATIONS

9.5 CHEMICAL & INDUSTRIAL APPLICATIONS

9.6 OTHERS

10 EUROPE BIOLOGICAL BUFFERS MARKET, BY END USER

10.1 OVERVIEW

10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES

10.3 BIOTECHNOLOGY COMPANIES

10.4 RESEARCH & ACADEMIC INSTITUTES

10.5 DIAGNOSTIC LABORATORIES

10.6 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CMOS

11 EUROPE BIOLOGICAL BUFFERS MARKET, BY REGION

11.1 EUROPE

11.1.1 GERMANY

11.1.2 U.K

11.1.3 FRANCE

11.1.4 ITALY

11.1.5 SPAIN

11.1.6 RUSSIA

11.1.7 SWITZERLAND

11.1.8 TURKEY

11.1.9 AUSTRIA

11.1.10 POLAND

11.1.11 IRELAND

11.1.12 NORWAY

11.1.13 REST OF EUROPE

12 EUROPE BIOLOGICAL BUFFERS MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: EUROPE

13 SWOT

14 COMPANY PROFILES

14.1 F. HOFFMANN-LA ROCHE LTD

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT UPDATES

14.2 BIO-RAD LABORATORIES, INC.

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENT

14.3 THERMO FISHER SCIENTIFIC, INC.

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT UPDATES

14.4 TAKARA BIO INC.

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENTS

14.5 MERCK KGAA, DARMSTADT, GERMANY

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENTS

14.6 ADVANCION CORPORATION

14.6.1 COMPANY SNAPSHOT

14.6.2 PRODUCT PORTFOLIO

14.6.3 RECENT DEVELOPMENT

14.7 AVANTOR, INC.

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENT

14.8 BECKMAN COULTER

14.8.1 COMPANY SNAPSHOT

14.8.2 PRODUCT PORTFOLIO

14.8.3 RECENT DEVELOPMENT

14.9 BIOSYNTH

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENT

14.1 FUJIFILM WAKO PURE CHEMICAL CORPORATION

14.10.1 COMPANY SNAPSHOT

14.10.2 PRODUCT PORTFOLIO

14.10.3 RECENT DEVELOPMENT

14.11 GOLDBIO

14.11.1 COMPANY SNAPSHOT

14.11.2 PRODUCT PORTFOLIO

14.11.3 RECENT DEVELOPMENT

14.12 HOPAX

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENT

14.13 HIMEDIA LABORATORIES

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENT

14.14 MP BIOMEDICALS.

14.14.1 COMPANY SNAPSHOT

14.14.2 PRODUCT PORTFOLIO

14.14.3 RECENT DEVELOPMENT

14.15 NACALAI TESQUE, INC.

14.15.1 COMPANY SNAPSHOT

14.15.2 PRODUCT PORTFOLIO

14.15.3 RECENT DEVELOPMENT

14.16 PROMEGA CORPORATION

14.16.1 COMPANY SNAPSHOT

14.16.2 PRODUCT PORTFOLIO

14.16.3 RECENT DEVELOPMENT

14.17 QIAGEN

14.17.1 COMPANY SNAPSHOT

14.17.2 REVENUE ANALYSIS

14.17.3 PRODUCT PORTFOLIO

14.17.4 RECENT DEVELOPMENT

14.18 REAGECON DIAGNOSTICS LTD

14.18.1 COMPANY SNAPSHOT

14.18.2 PRODUCT PORTFOLIO

14.18.3 RECENT DEVELOPMENT

14.19 SANTA CRUZ BIOTECHNOLOGY INC.

14.19.1 COMPANY SNAPSHOT

14.19.2 PRODUCT PORTFOLIO

14.19.3 RECENT DEVELOPMENT

14.2 SERVA ELECTROPHORESIS GMBH

14.20.1 COMPANY SNAPSHOT

14.20.2 PRODUCT PORTFOLIO

14.20.3 RECENT DEVELOPMENT

14.21 TEVA PHARMACEUTICALS USA, INC.

14.21.1 COMPANY SNAPSHOT

14.21.2 REVENUE ANALYSIS

14.21.3 PRODUCT PORTFOLIO

14.21.4 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

表格列表

TABLE 1 EUROPE BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)

TABLE 2 EUROPE GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY REGION, 2018-2035 (USD THOUSAND)

TABLE 3 EUROPE GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 4 EUROPE TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 5 EUROPE HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND

TABLE 6 EUROPE MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 7 EUROPE MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 8 EUROPE BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 9 EUROPE OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY REGION, 2018-2035 (USD THOUSAND)

TABLE 10 EUROPE OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 11 EUROPE PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 12 EUROPE ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 13 EUROPE CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 14 EUROPE AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 15 EUROPE BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)

TABLE 16 EUROPE POWDER IN BIOLOGICAL BUFFERS MARKET, BY REGION, 2018-2035 (USD THOUSAND)

TABLE 17 EUROPE LIQUID IN BIOLOGICAL BUFFERS MARKET, BY REGION, 2018-2035 (USD THOUSAND)

TABLE 18 EUROPE BIOLOGICAL BUFFERS MARKET, BY APPLICATION,2018-2035 (USD THOUSAND)

TABLE 19 EUROPE PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY REGION, 2018-2035 (USD THOUSAND)

TABLE 20 EUROPE PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 21 EUROPE CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY REGION, 2018-2035 (USD THOUSAND)

TABLE 22 EUROPE CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 23 EUROPE CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY REGION, 2018-2035 (USD THOUSAND)

TABLE 24 EUROPE CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 25 EUROPE CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY REGION, 2018-2035 (USD THOUSAND)

TABLE 26 EUROPE CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 27 EUROPE OTHERS IN BIOLOGICAL BUFFERS MARKET, BY REGION, 2018-2035 (USD THOUSAND)

TABLE 28 EUROPE BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)

TABLE 29 EUROPE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES IN ORTHODONTIC SUPPLIES MARKET, BY REGION, 2018-2035 (USD THOUSAND)

TABLE 30 EUROPE BIOTECHNOLOGY COMPANIES IN ORTHODONTIC SUPPLIES MARKET, BY REGION, 2018-2035 (USD THOUSAND)

TABLE 31 EUROPE RESEARCH & ACADEMIC INSTITUTES IN ORTHODONTIC SUPPLIES MARKET, BY REGION, 2018-2035 (USD THOUSAND)

TABLE 32 EUROPE DIAGNOSTIC LABORATORIES IN ORTHODONTIC SUPPLIES MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 33 EUROPE CONTRACT RESEARCH ORGANIZATIONS (CROS) IN ORTHODONTIC SUPPLIES MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 34 EUROPE BIOLOGICAL BUFFERS MARKET, BY COUNTRY, 2018-2035 (USD THOUSAND)

TABLE 35 EUROPE BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)

TABLE 36 EUROPE GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 37 EUROPE TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 38 EUROPE HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 39 EUROPE MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 40 EUROPE MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 41 EUROPE BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)

TABLE 42 EUROPE OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 43 EUROPE PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 44 EUROPE ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 45 EUROPE CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 46 EUROPE AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 47 EUROPE BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)

TABLE 48 EUROPE BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)

TABLE 49 EUROPE PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 50 EUROPE CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 51 EUROPE CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 52 EUROPE CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 53 EUROPE BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)

TABLE 54 GERMANY BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)

TABLE 55 GERMANY GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 56 GERMANY TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 57 GERMANY HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 58 GERMANY MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 59 GERMANY MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 60 GERMANY BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)

TABLE 61 GERMANY OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 62 GERMANY PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 63 GERMANY ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 64 GERMANY CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 65 GERMANY AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 66 GERMANY BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)

TABLE 67 GERMANY BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)

TABLE 68 GERMANY PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 69 GERMANY CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 70 GERMANY CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 71 GERMANY CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 72 GERMANY BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)

TABLE 73 U.K. BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)

TABLE 74 U.K. GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 75 U.K. TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 76 U.K. HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 77 U.K. MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 78 U.K. MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 79 U.K. BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)

TABLE 80 U.K. OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 81 U.K. PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 82 U.K. ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 83 U.K. CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 84 U.K. AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 85 U.K. BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)

TABLE 86 U.K. BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)

TABLE 87 U.K. PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 88 U.K. CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 89 U.K. CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 90 U.K. CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 91 U.K. BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)

TABLE 92 FRANCE BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)

TABLE 93 FRANCE GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 94 FRANCE TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 95 FRANCE HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 96 FRANCE MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 97 FRANCE MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 98 FRANCE BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)

TABLE 99 FRANCE OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 100 FRANCE PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 101 FRANCE ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 102 FRANCE CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 103 FRANCE AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 104 FRANCE BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)

TABLE 105 FRANCE BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)

TABLE 106 FRANCE PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 107 FRANCE CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 108 FRANCE CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 109 FRANCE CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 110 FRANCE BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)

TABLE 111 ITALY BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)

TABLE 112 ITALY GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 113 ITALY TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 114 ITALY HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 115 ITALY MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 116 ITALY MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 117 ITALY BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)

TABLE 118 ITALY OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 119 ITALY PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 120 ITALY ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 121 ITALY CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 122 ITALY AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 123 ITALY BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)

TABLE 124 ITALY BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)

TABLE 125 ITALY PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 126 ITALY CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 127 ITALY CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 128 ITALY CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 129 ITALY BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)

TABLE 130 SPAIN BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)

TABLE 131 SPAIN GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 132 SPAIN TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 133 SPAIN HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 134 SPAIN MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 135 SPAIN MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 136 SPAIN BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)

TABLE 137 SPAIN OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 138 SPAIN PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 139 SPAIN ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 140 SPAIN CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 141 SPAIN AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 142 SPAIN BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)

TABLE 143 SPAIN BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)

TABLE 144 SPAIN PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 145 SPAIN CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 146 SPAIN CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 147 SPAIN CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 148 SPAIN BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)

TABLE 149 RUSSIA BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)

TABLE 150 RUSSIA GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 151 RUSSIA TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 152 RUSSIA HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 153 RUSSIA MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 154 RUSSIA MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 155 RUSSIA BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)

TABLE 156 RUSSIA OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 157 RUSSIA PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 158 RUSSIA ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 159 RUSSIA CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 160 RUSSIA AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 161 RUSSIA BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)

TABLE 162 RUSSIA BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)

TABLE 163 RUSSIA PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 164 RUSSIA CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 165 RUSSIA CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 166 RUSSIA CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 167 RUSSIA BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)

TABLE 168 NETHERLAND

TABLE 169 NETHERLANDS BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)

TABLE 170 NETHERLANDS GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 171 NETHERLANDS TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 172 NETHERLANDS HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 173 NETHERLANDS MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 174 NETHERLANDS MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 175 NETHERLANDS BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)

TABLE 176 NETHERLANDS OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 177 NETHERLANDS PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 178 NETHERLANDS ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 179 NETHERLANDS CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 180 NETHERLANDS AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 181 NETHERLANDS BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)

TABLE 182 NETHERLANDS BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)

TABLE 183 NETHERLANDS PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 184 NETHERLANDS CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 185 NETHERLANDS CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 186 NETHERLANDS CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 187 NETHERLANDS BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)

TABLE 188 SWITZERLAND BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)

TABLE 189 SWITZERLAND GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 190 SWITZERLAND TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 191 SWITZERLAND HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 192 SWITZERLAND MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 193 SWITZERLAND MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 194 SWITZERLAND BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)

TABLE 195 SWITZERLAND OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 196 SWITZERLAND PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 197 SWITZERLAND ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 198 SWITZERLAND CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 199 SWITZERLAND AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 200 SWITZERLAND BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)

TABLE 201 SWITZERLAND BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)

TABLE 202 SWITZERLAND PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 203 SWITZERLAND CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 204 SWITZERLAND CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 205 SWITZERLAND CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 206 SWITZERLAND BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)

TABLE 207 TURKEY BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)

TABLE 208 TURKEY GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 209 TURKEY TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 210 TURKEY HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 211 TURKEY MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 212 TURKEY MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 213 TURKEY BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)

TABLE 214 TURKEY OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 215 TURKEY PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 216 TURKEY ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 217 TURKEY CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 218 TURKEY AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 219 TURKEY BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)

TABLE 220 TURKEY BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)

TABLE 221 TURKEY PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 222 TURKEY CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 223 TURKEY CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 224 TURKEY CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 225 TURKEY BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)

TABLE 226 AUSTRIA BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)

TABLE 227 AUSTRIA GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 228 AUSTRIA TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 229 AUSTRIA HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 230 AUSTRIA MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 231 AUSTRIA MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 232 AUSTRIA BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)

TABLE 233 AUSTRIA OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 234 AUSTRIA PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 235 AUSTRIA ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 236 AUSTRIA CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 237 AUSTRIA AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 238 AUSTRIA BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)

TABLE 239 AUSTRIA BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)

TABLE 240 AUSTRIA PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 241 AUSTRIA CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 242 AUSTRIA CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 243 AUSTRIA CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 244 AUSTRIA BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)

TABLE 245 POLAND BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)

TABLE 246 POLAND GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 247 POLAND TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 248 POLAND HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 249 POLAND MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 250 POLAND MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 251 POLAND BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)

TABLE 252 POLAND OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 253 POLAND PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 254 POLAND ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 255 POLAND CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 256 POLAND AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 257 POLAND BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)

TABLE 258 POLAND BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)

TABLE 259 POLAND PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 260 POLAND CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 261 POLAND CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 262 POLAND CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 263 POLAND BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)

TABLE 264 IRELAND BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)

TABLE 265 IRELAND GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 266 IRELAND TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 267 IRELAND HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 268 IRELAND MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 269 IRELAND MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 270 IRELAND BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)

TABLE 271 IRELAND OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 272 IRELAND PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 273 IRELAND ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 274 IRELAND CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 275 IRELAND AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 276 IRELAND BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)

TABLE 277 IRELAND BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)

TABLE 278 IRELAND PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 279 IRELAND CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 280 IRELAND CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 281 IRELAND CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 282 IRELAND BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)

TABLE 283 NORWAY BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)

TABLE 284 NORWAY GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 285 NORWAY TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 286 NORWAY HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 287 NORWAY MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 288 NORWAY MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 289 NORWAY BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)

TABLE 290 NORWAY OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 291 NORWAY PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 292 NORWAY ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 293 NORWAY CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 294 NORWAY AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 295 NORWAY BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)

TABLE 296 NORWAY BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)

TABLE 297 NORWAY PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 298 NORWAY CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 299 NORWAY CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 300 NORWAY CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)

TABLE 301 NORWAY BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)

TABLE 302 REST OF EUROPE BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)

图片列表

FIGURE 1 EUROPE BIOLOGICAL BUFFERS MARKET: SEGMENTATION

FIGURE 2 EUROPE BIOLOGICAL BUFFERS MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE BIOLOGICAL BUFFERS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE BIOLOGICAL BUFFERS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE BIOLOGICAL BUFFERS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE BIOLOGICAL BUFFERS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE BIOLOGICAL BUFFERS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE BIOLOGICAL BUFFERS MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 EUROPE BIOLOGICAL BUFFERS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE BIOLOGICAL BUFFERS MARKET: SEGMENTATION

FIGURE 11 RISING PREVALENCE OF CHRONIC DISEASES IS EXPECTED TO DRIVE THE EUROPE BIOLOGICAL BUFFERS MARKET GROWTH IN THE FORECAST PERIOD OF 2025 TO 2035

FIGURE 12 GOODS BUFFERS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE BIOLOGICAL BUFFERS MARKET IN THE FORECAST PERIOD OF 2025 & 2035

FIGURE 13 EUROPE BIOLOGICAL BUFFERS MARKET EXECUTIVE SUMMARY

FIGURE 14 STRATEGIC DECISIONS

FIGURE 15 DROC

FIGURE 16 EUROPE BIOLOGICAL BUFFERS MARKET: BY BUFFER TYPE, 2024

FIGURE 17 EUROPE BIOLOGICAL BUFFERS MARKET: BY BUFFER TYPE, 2025-2035 (USD THOUSAND)

FIGURE 18 EUROPE BIOLOGICAL BUFFERS MARKET: BY BUFFER TYPE, CAGR (2025-2035)

FIGURE 19 EUROPE BIOLOGICAL BUFFERS MARKET: BY BUFFER TYPE, LIFELINE CURVE

FIGURE 20 EUROPE BIOLOGICAL BUFFERS MARKET: BY FORMULATION, 2024

FIGURE 21 EUROPE BIOLOGICAL BUFFERS MARKET: BY FORMULATION, 2025-2035 (USD THOUSAND)

FIGURE 22 EUROPE BIOLOGICAL BUFFERS MARKET: BY FORMULATION, CAGR (2025-2035)

FIGURE 23 EUROPE BIOLOGICAL BUFFERS MARKET: BY FORMULATION, LIFELINE CURVE

FIGURE 24 EUROPE BIOLOGICAL BUFFERS MARKET: BY APPLICATION, 2024

FIGURE 25 EUROPE BIOLOGICAL BUFFERS MARKET: BY APPLICATION, 2025-2035 (USD THOUSAND)

FIGURE 26 EUROPE BIOLOGICAL BUFFERS MARKET: BY APPLICATION, CAGR (2025-2035)

FIGURE 27 EUROPE BIOLOGICAL BUFFERS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 28 EUROPE BIOLOGICAL BUFFERS MARKET: BY END USER, 2024

FIGURE 29 EUROPE BIOLOGICAL BUFFERS MARKET: BY END USER, 2025-2035 (USD THOUSAND)

FIGURE 30 EUROPE BIOLOGICAL BUFFERS MARKET: BY END USER, CAGR (2025-2035)

FIGURE 31 EUROPE BIOLOGICAL BUFFERS MARKET: BY END USER, LIFELINE CURVE

FIGURE 32 EUROPE BIOLOGICAL BUFFERS MARKET: SNAPSHOT (2024)

FIGURE 33 EUROPE BIOLOGICAL BUFFERS MARKET: COMPANY SHARE 2024 (%)

查看详细信息 Right Arrow

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。

DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。

Frequently Asked Questions

市场是基于 歐洲生物緩衝液市場細分，按緩衝液類型（商品緩衝液和其他鹽基緩衝液）、配方（粉末和液體）、應用（製藥和生物製藥、細胞培養和分子生物學、臨床和診斷應用、化學和工業應用等）、最終用戶（製藥和生物製藥公司、生物技術公司、研究和學術機構、診斷實驗室、合約研究組織 (CRO） 进行细分的。
在2024年，歐洲生物緩衝液市場的规模估计为246.70 USD Million美元。
歐洲生物緩衝液市場预计将在2025年至2035年的预测期内以CAGR 6.9%的速度增长。
市场上的主要参与者包括F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Takara Bio Inc., Merck KGaA。

浏览相关页面

Banner
Testimonial
Image
David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.
Image
Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Image
Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Image
Business Intelligence and Analytics, Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Image
Competition Analyst, Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Image
Marketing Director, Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

Image
COO, A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Image
Marketing Director, Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Image
Product manager, Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Image
Investor relations, GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Image
Market Analyst, Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Image
Andrew - Senior Global Marketing Manager, Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Image
Amarildo - Manager, Global Strategic Alignment MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Image
Tor Hammer Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Image
Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Image
Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future